Five-fraction prostate and pelvic SABR showed durable control with low late toxicity
Five weekly SABR fractions to prostate and pelvic nodes produced 10.5% five-year biochemical failure with low persistent gastrointestinal and urinary toxicity.
Five weekly SABR fractions to prostate and pelvic nodes produced 10.5% five-year biochemical failure with low persistent gastrointestinal and urinary toxicity.
ASTRO expands radiation therapy recommendations across locally advanced, recurrent and oligometastatic pancreatic cancer, with new guidance on dose escalation and adaptation.
ASTuTE biomarker testing changed 27.5% of shared decisions and reduced planned short-term ADT use from 37% to 12.5%.
Six-fraction chemoradiation shortened median survival from 21 to 13 months and substantially increased radiation necrosis compared with standard treatment.
EXCERPT At five years, chest wall radiotherapy modestly worsened local symptoms but did not significantly affect overall quality of life or major functional domains.
More than 56,000 theoretically eligible European patients lived in areas with no proton access or critical capacity shortages in 2025.
Five-year progression-free and overall survival were 55.4% and 64.6%, with metastatic status and histologic response remaining major prognostic factors.
Three-year outcomes numerically favored 50.4 Gy over 60 Gy, while multivariable analysis found no significant survival advantage from either dose.
COMPPARE enrolled 2,524 patients from 51 institutions in 52 months, with Black participation reaching 16% of the cohort.
Seventy-three percent of failures after nonadherent sacral contouring involved sectors that guidelines recommended including in the clinical target volume.
Pelvic insufficiency fractures occurred in 29.2% of patients, with postmenopause and elevated baseline t-PINP independently predicting risk.
In 2024, only 3.2% of English patients began curative radiotherapy within the 49-day target despite rapidly rising demand.
COG guidelines standardize pediatric radiotherapy simulation across treatment sites and techniques
Adding low-dose olaparib increased grade 3 dermatitis from 5.5% to 24.7% during postmastectomy radiotherapy for inflammatory breast cancer.
Five-year overall survival was 78.1% with short-course total neoadjuvant therapy versus 69.7% with long-course chemoradiotherapy.